Clinical trials: Insufficient Metabolic Control
Type 2 Diabetes
Add-on to Thiazolidinedione (TZD) Failures
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone.
- Trial name
- NCT00683878
- Testing
- Dapagliflozin, Thiazolidinedione (Pioglitazone)
- Where
- 89 sites in United States, Argentina and 7 more
- Volunteers
- 972 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using…
- Trial name
- ACHIEVE-2 (NCT06192108)
- Testing
- Orforglipron, Dapagliflozin
- Where
- 74 sites in United States, China and 4 more
- Volunteers
- 962 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
This study is a multicenter, randomized, double-blind (with open-label dose levels and active comparator), parallel-group, placebo- and active-controlled Phase 2 clinical trial aimed at evaluating the efficacy, safety…
- Trial name
- NCT07109700
- Testing
- HDM1005 1, HDM1005 2, HDM1005 3
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Japanese male and female patients with Type 2 Diabetes and aged ≥ 20 years old, with inadequate glycemic control on insulin defined as Haemoglobin A1c ≥ 7.2% and < 11% will be enrolled into the wash-out phase or directly into the…
- Trial name
- NCT02157298
- Testing
- Dapagliflozin 5 mg
- Where
- 14 sites in Japan
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose…
- Trial name
- NCT06260722
- Testing
- Retatrutide, Semaglutide
- Where
- 77 sites in United States, Argentina and 3 more
- Volunteers
- 1,250 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)
After 24 weeks of treatment evaluate the efficacy and security.
- Trial name
- NCT00832390
- Testing
- sitagliptin phosphate
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes, High Blood Sugar
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
This is a 24-week randomised, multi-centre phase III study to evaluate the efficacy and safety of dapagliflozin as monotherapy in Japanese subjects with Type 2 diabetes mellitus who have inadequate glycemic control with diet and…
- Trial name
- NCT01294423
- Testing
- Dapagliflozin
- Where
- 26 sites in Japan
- Volunteers
- 261 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment as add-on therapy to metformin in…
- Trial name
- NCT01215097
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 306 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Dose-Range Finding Study for MK0893 (0893-008)
A study to compare MK0893 to metformin or placebo for patients with Type 2 diabetes (Diabetes Mellitus).
- Trial name
- NCT00479466
- Testing
- MK0893, Metformin
- Volunteers
- 342 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus (T2DM)
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet…
- Trial name
- HDNO-1605 (NCT06647550)
- Testing
- HD-6277 100mg, HD-6277 50mg, HD-6277 25mg
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Hyundai Pharm
Type 2 Diabetes
Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg
The purpose of this study was to compare effect of Saxagliptin as add-on to Metformin on 24-hour mean weighted glucose (MWG) to the effect of uptitrating Metformin in subjects with T2DM inadequately controlled on metformin alone.
- Trial name
- NCT00918138
- Testing
- Saxagliptin, Metformin XR
- Where
- 21 sites in United States, Argentina and 2 more
- Volunteers
- 219 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Tenelia Triple Combination Study
After a screening, a 2-week, single-blind placebo run-in, 200 patients will be randomized in a 1 : 1 ratio to the addition of either once-daily Teneligliptin 20mg or sitagliptin 100mg to ongoing stable doses of glimepiride in…
- Trial name
- TETRIS (NCT02567994)
- Testing
- Teneligliptin
- Where
- South Korea
- Volunteers
- 201 people
- Sponsor
- Handok Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients
The objective of the current study is to investigate the efficacy, safety and tolerability of several doses of BI 1356 BS (0.5, 2.5 and 5 mg daily) compared to placebo over 12 weeks of treatment in patients with Type 2 diabetes…
- Trial name
- NCT00328172
- Testing
- BI 1356 dose 3 once daily, BI 1356 dose 2 once daily, BI 1356 dose 1 once daily
- Where
- 71 sites in United States, Australia and 4 more
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Obesity
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
This trial will evaluate use of BI 10773 as add-on to insulin regimen alone or with metformin in patients with typr 2 diabetes. Both lowering glucose and HbA1c and reducing the use of insulin in this population would provide…
- Trial name
- NCT01306214
- Testing
- BI 10773
- Where
- 103 sites in United States, Belgium and 12 more
- Volunteers
- 566 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Primary Objective: To demonstrate the superiority of Sotagliflozin 200 milligrams (mg) and Sotagliflozin 400 mg versus placebo on HbA1c reduction at 26 Weeks in participants with Type 2 diabetes who have inadequate glycemic…
- Trial name
- SOTA-CKD3 (NCT03242252)
- Testing
- Sotagliflozin
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 787 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment.This study will be conducted at…
- Trial name
- DERIVE (NCT02413398)
- Testing
- Dapagliflozin 10 mg
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 321 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes.
- Trial name
- NCT00263276
- Testing
- dapagliflozin, metformin
- Where
- 144 sites in United States, Canada and 2 more
- Volunteers
- 389 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM)
Embecta AID System in Adults With Type 2 Diabetes
This is a multi-center, randomized control study that will evaluate the safety and effectiveness of the embecta Automated Insulin Delivery System in adults with Type 2 diabetes requiring insulin therapy
- Conditions
- Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 DM, T2DM With Inadequate Glycemic Control
- Trial name
- EMBRACE-T2D (NCT06692153)
- Testing
- An AID System., Standard of Care (SC)
- Where
- 9 sites in United States
- Sponsor
- Embecta Corp.
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or previously treated type 2 diabetic patients…
- Trial name
- NCT01087502
- Testing
- Glimepiride, Linagliptin
- Where
- 52 sites in United States, Australia and 7 more
- Volunteers
- 241 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
This study is a multicenter, randomized, open-label, parallel-group, phase 3 clinical trial aimed at evaluating the efficacy and safety of HDM1005 versus active comparator in subjects with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT07417306
- Testing
- HDM1005 1, HDM1005 2, Mazdutide
- Where
- China
- Volunteers
- 912 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.